Review



human cancer cell line expression profiles and somatic mutation data  (Broad Institute Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Broad Institute Inc human cancer cell line expression profiles and somatic mutation data
    Human Cancer Cell Line Expression Profiles And Somatic Mutation Data, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/transcriptional+profiling+of+human+cancer+cell+lines/pm40595395-261-21-35
    Average 90 stars, based on 1 article reviews
    human cancer cell line expression profiles and somatic mutation data - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Mutagenesis:

    Article Title: Investigating the role of senescence biomarkers in colorectal cancer heterogeneity by bulk and single-cell RNA sequencing
    Article Snippet: .. Based on previous study , the somatic mutation data and expression profile data of human cancer cell lines (CCLs) were downloaded from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) project . .. Then, the sensitivity data for 1448 compounds to 482 CCLs was acquired from the PRISM Repurposing dataset (PRISM; https://depmap.org/portal/prism/ ) and the sensitivity data for 481 compounds to 835 CCLs was acquired from Cancer Therapeutics Response Portal (CTRP; https://portals.broadinstitute.org/ctrp ).

    Article Title: Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study.
    Article Snippet: CNVs in focal genomic loci were delineated using GISTIC2.0 via GenePattern. .. Screening and validation of potential therapeutic compounds for high CAIPS scores in HCC The human cancer cell line expression profiles and somatic mutation data were acquired from the Cancer Cell Line Encyclopedia project at the Broad Institute (https://portals.broadinstitute.org/ccle/)73. .. Drug sensitivity matrices were curated from Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) (https://depmap.org/portal/prism/) and Cancer Therapeutics Response Portal (CTRP) (https://portals.broadinstitute.org/ctrp).

    Expressing:

    Article Title: Investigating the role of senescence biomarkers in colorectal cancer heterogeneity by bulk and single-cell RNA sequencing
    Article Snippet: .. Based on previous study , the somatic mutation data and expression profile data of human cancer cell lines (CCLs) were downloaded from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) project . .. Then, the sensitivity data for 1448 compounds to 482 CCLs was acquired from the PRISM Repurposing dataset (PRISM; https://depmap.org/portal/prism/ ) and the sensitivity data for 481 compounds to 835 CCLs was acquired from Cancer Therapeutics Response Portal (CTRP; https://portals.broadinstitute.org/ctrp ).

    Article Title: Pyroptosis-related lncRNAs: A novel prognosis signature of colorectal cancer
    Article Snippet: .. After that, expression profile and somatic mutations data of human cancer cell lines were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) project ( https://portals.broadinstitute.org/ccle/ ) ( ). ..

    Article Title: Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study.
    Article Snippet: CNVs in focal genomic loci were delineated using GISTIC2.0 via GenePattern. .. Screening and validation of potential therapeutic compounds for high CAIPS scores in HCC The human cancer cell line expression profiles and somatic mutation data were acquired from the Cancer Cell Line Encyclopedia project at the Broad Institute (https://portals.broadinstitute.org/ccle/)73. .. Drug sensitivity matrices were curated from Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) (https://depmap.org/portal/prism/) and Cancer Therapeutics Response Portal (CTRP) (https://portals.broadinstitute.org/ctrp).

    Article Title: USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells
    Article Snippet: .. TCGA PANCAN samples used in this analysis are shown in . (E) Expression of USP15 from transcriptional profiling of human cancer cell lines (CCLE, Broad Institute). (F) USP15 normalized expression levels in a panel of leukemia cell lines as assessed by qRT-PCR and RNA-seq by CCLE. ..

    other:

    Article Title: Machine Learning-Based Integrated Analysis of PANoptosis Patterns in Acute Myeloid Leukemia Reveals a Signature Predicting Survival and Immunotherapy
    Article Snippet: Transcriptome data of human cancer cell lines (CCLs) were the Broad Institute-Cancer Cell Line Encyclopedia project (CCLE, https://sites.broadinstitute.org/ccle/ ) and the CERES scores, the score to evaluate the dependency of the certain gene in the CCL, which indicated that the score was negative correlation with the possible significance of the gene in cell proliferation of the certain CCL, were the dependency map portal (DepMap, https://depmap.org/portal/ )

    Biomarker Discovery:

    Article Title: Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study.
    Article Snippet: CNVs in focal genomic loci were delineated using GISTIC2.0 via GenePattern. .. Screening and validation of potential therapeutic compounds for high CAIPS scores in HCC The human cancer cell line expression profiles and somatic mutation data were acquired from the Cancer Cell Line Encyclopedia project at the Broad Institute (https://portals.broadinstitute.org/ccle/)73. .. Drug sensitivity matrices were curated from Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) (https://depmap.org/portal/prism/) and Cancer Therapeutics Response Portal (CTRP) (https://portals.broadinstitute.org/ctrp).

    Quantitative RT-PCR:

    Article Title: USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells
    Article Snippet: .. TCGA PANCAN samples used in this analysis are shown in . (E) Expression of USP15 from transcriptional profiling of human cancer cell lines (CCLE, Broad Institute). (F) USP15 normalized expression levels in a panel of leukemia cell lines as assessed by qRT-PCR and RNA-seq by CCLE. ..

    RNA Sequencing:

    Article Title: USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells
    Article Snippet: .. TCGA PANCAN samples used in this analysis are shown in . (E) Expression of USP15 from transcriptional profiling of human cancer cell lines (CCLE, Broad Institute). (F) USP15 normalized expression levels in a panel of leukemia cell lines as assessed by qRT-PCR and RNA-seq by CCLE. ..



    Similar Products

    86
    Caris Life Sciences tumor mutational profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tumor Mutational Profiles, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/comprehensive+molecular+profiling/pmc12420367-92-2-16
    Average 86 stars, based on 1 article reviews
    tumor mutational profiles - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Broad Institute Inc human cancer cell line expression profiles and somatic mutation data
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Human Cancer Cell Line Expression Profiles And Somatic Mutation Data, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/transcriptional+profiling+of+human+cancer+cell+lines/pm40595395-261-21-35
    Average 90 stars, based on 1 article reviews
    human cancer cell line expression profiles and somatic mutation data - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Illumina Inc somatic mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Somatic Mutation Profiles, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/somatic+mutation+profiles/pm40435135-1-29-19
    Average 90 stars, based on 1 article reviews
    somatic mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    Bio-Rad oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Oncocompasstm Target Cancer Mutation Profiling Liquid Kit Burning Rock Biotech N A Ddpcrtm Supermix For Probes, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/Droplet+PCR+Supermix/pmc12147912__mmc2-421-104-121
    Average 99 stars, based on 1 article reviews
    oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    95
    Zymo Research mutational profiling map fragmentation buffer
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Mutational Profiling Map Fragmentation Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/Digestion+Buffer/pmc12000875-61-8-54
    Average 95 stars, based on 1 article reviews
    mutational profiling map fragmentation buffer - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    90
    Broad Institute Inc somatic mutation data and expression profile data of human cancer cell lines (ccls)
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Somatic Mutation Data And Expression Profile Data Of Human Cancer Cell Lines (Ccls), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/transcriptional+profiling+of+human+cancer+cell+lines/pmc11362543-138-10-23
    Average 90 stars, based on 1 article reviews
    somatic mutation data and expression profile data of human cancer cell lines (ccls) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Seegene Technologies rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Rt Pcr Detecting Specific Spike Mutation Profiles Allplex Sars Cov 2 Variants I Assay, supplied by Seegene Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/allplex+sars+cov+2+assay/pm38570699-51-23-34
    Average 90 stars, based on 1 article reviews
    rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    BioResource International Inc mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Mutation Profiles, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/mutation+profiles/pm38639832-24-37-17
    Average 90 stars, based on 1 article reviews
    mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Broad Institute Inc tcga mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tcga Mutation Profiles, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/tcga+mutation+profiles/pmc10980029__media___1-231-6-14
    Average 90 stars, based on 1 article reviews
    tcga mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques:

    Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques: Protein-Protein interactions, Amplification